Novavax (NVAX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $11.26, -12.17% vs the prior close of $12.82.
- Volume 9.87M shares, 1.5x its 50-day average.
- New SEC filings: SCHEDULE 13G (Oct 16, 2026), SCHEDULE 13D/A (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
NVAX slides 12.2% to $11.26. Closed at $11.26, -12.17% vs the prior close of $12.82. Day range $11.11–$12.84, opened at $12.71.
NVAX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — NVAX slides 12.2% to $11.26
- Closed at $11.26, -12.17% vs the prior close of $12.82. Day range $11.11–$12.84, opened at $12.71.
- Volume was 9.87M shares, 1.5x its 50-day average of 6.55M.
- Price is +12.4% vs its 50-day average ($10.02) and +23.0% vs its 200-day average ($9.16).
- 52-week range $6.20–$13.39; today's close sits at 70% of that range, 15.9% below the 52-week high.
Oct 15, 2026 — NVAX rises 1.4% to $12.82
- Closed at $12.82, +1.42% vs the prior close of $12.64. Day range $12.18–$13.25, opened at $12.50.
- Volume was 7.36M shares, 1.1x its 50-day average of 6.47M.
- Price is +28.9% vs its 50-day average ($9.95) and +40.4% vs its 200-day average ($9.13).
- 52-week range $6.20–$13.39; today's close sits at 92% of that range, 4.3% below the 52-week high.
Oct 14, 2026 — NVAX dips 1.4% to $12.64
- Closed at $12.64, -1.40% vs the prior close of $12.82. Day range $12.57–$13.34, opened at $12.69.
- Volume was 8.55M shares, 1.3x its 50-day average of 6.37M.
- Price is +28.4% vs its 50-day average ($9.85) and +38.9% vs its 200-day average ($9.10).
- 52-week range $6.20–$13.39; today's close sits at 90% of that range, 5.6% below the 52-week high.
Oct 13, 2026 — NVAX rises 1.3% to $12.82, a 52-week high
- Closed at $12.82, +1.26% vs the prior close of $12.66. Day range $12.21–$13.13, opened at $12.44.
- Volume was 8.40M shares, 1.3x its 50-day average of 6.25M.
- Price is +31.5% vs its 50-day average ($9.75) and +41.3% vs its 200-day average ($9.07).
- 52-week range $6.20–$13.39; today's close sits at 92% of that range, 4.3% below the 52-week high.
Oct 12, 2026 — NVAX dips 0.7% to $12.66
- Closed at $12.66, -0.71% vs the prior close of $12.75. Day range $12.19–$12.96, opened at $12.61.
- Volume was 8.50M shares, 1.4x its 50-day average of 6.15M.
- Price is +31.4% vs its 50-day average ($9.64) and +40.0% vs its 200-day average ($9.04).
- 52-week range $6.20–$13.39; today's close sits at 90% of that range, 5.5% below the 52-week high.
Oct 9, 2026 — NVAX jumps 15.8% to $12.75, a 52-week high on 3.3x normal volume
- Closed at $12.75, +15.80% vs the prior close of $11.01. Day range $11.03–$13.04, opened at $11.17.
- Volume was 19.03M shares, 3.3x its 50-day average of 5.83M — unusually heavy trading.
- Price is +33.8% vs its 50-day average ($9.53) and +41.4% vs its 200-day average ($9.01).
- 52-week range $6.20–$13.39; today's close sits at 91% of that range, 4.8% below the 52-week high.
Oct 8, 2026 — NVAX dips 1.9% to $11.01, 3 down days in a row
- Closed at $11.01, -1.87% vs the prior close of $11.22. Day range $10.76–$11.18, opened at $11.01.
- Volume was 6.21M shares, 1.1x its 50-day average of 5.75M.
- Price is +16.8% vs its 50-day average ($9.42) and +22.5% vs its 200-day average ($8.99).
- 52-week range $6.20–$13.39; today's close sits at 67% of that range, 17.8% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — NVAX dips 0.9% to $11.22
- Closed at $11.22, -0.88% vs the prior close of $11.32. Day range $10.90–$11.75, opened at $11.01.
- Volume was 8.38M shares, 1.5x its 50-day average of 5.64M.
- Price is +20.0% vs its 50-day average ($9.35) and +25.2% vs its 200-day average ($8.96).
- 52-week range $6.20–$13.39; today's close sits at 70% of that range, 16.2% below the 52-week high.
Oct 6, 2026 — NVAX slides 9.9% to $11.32 on 3.7x normal volume
- Closed at $11.32, -9.87% vs the prior close of $12.56. Day range $10.88–$13.33, opened at $12.35.
- Volume was 19.41M shares, 3.7x its 50-day average of 5.32M — unusually heavy trading.
- Price is +22.1% vs its 50-day average ($9.27) and +26.6% vs its 200-day average ($8.94).
- 52-week range $6.20–$13.39; today's close sits at 71% of that range, 15.5% below the 52-week high.
Oct 5, 2026 — NVAX jumps 20.1% to $12.56, a 52-week high on 6.0x normal volume
- Closed at $12.56, +20.08% vs the prior close of $10.46. Day range $10.28–$13.39, opened at $10.47.
- Volume was 28.70M shares, 6.0x its 50-day average of 4.81M — unusually heavy trading.
- Price is +36.6% vs its 50-day average ($9.20) and +40.9% vs its 200-day average ($8.92).
- 52-week range $6.20–$13.39; today's close sits at 88% of that range, 6.2% below the 52-week high.
Oct 2, 2026 — NVAX dips 1.3% to $10.46, 3 down days in a row
- Closed at $10.46, -1.32% vs the prior close of $10.60. Day range $10.33–$10.86, opened at $10.80.
- Volume was 4.02M shares, 0.8x its 50-day average of 4.78M.
- Price is +15.0% vs its 50-day average ($9.10) and +17.7% vs its 200-day average ($8.89).
- 52-week range $6.20–$11.97; today's close sits at 74% of that range, 12.6% below the 52-week high.
- That makes 3 straight losses.
NVAX latest news & SEC filings
Every SEC filing by or about NVAX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 16, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $56.70M (prior year $239.24M) (-76.3% vs Jun 30, 2025)
- Net income: -$53.39M (prior year $106.51M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.32 (prior year $0.62) (loss widened vs Jun 30, 2025)
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jun 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade NVAX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 6, 2026, Feb 26, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.05% (largest 20.1%). That is a volatile stock.
- Liquidity: about 8.62M shares (≈$97.07M) trade per day on average.
- 52-week position: $11.26 vs a range of $6.20–$13.39 (70% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 6, 2026; 10-Q Aug 6, 2026; 8-K Jun 23, 2026.
- Share count: 164.95M shares outstanding (Jul 31, 2026), +1.6% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
NVAX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 12.71 | 12.84 | 11.11 | 11.26 | 9.87M |
| Oct 15, 2026 | 12.50 | 13.25 | 12.18 | 12.82 | 7.37M |
| Oct 14, 2026 | 12.69 | 13.34 | 12.57 | 12.64 | 8.55M |
| Oct 13, 2026 | 12.44 | 13.13 | 12.21 | 12.82 | 8.40M |
| Oct 12, 2026 | 12.61 | 12.96 | 12.19 | 12.66 | 8.50M |
| Oct 9, 2026 | 11.17 | 13.04 | 11.03 | 12.75 | 19.03M |
| Oct 8, 2026 | 11.01 | 11.18 | 10.76 | 11.01 | 6.21M |
| Oct 7, 2026 | 11.01 | 11.75 | 10.90 | 11.22 | 8.38M |
| Oct 6, 2026 | 12.35 | 13.33 | 10.88 | 11.32 | 19.41M |
| Oct 5, 2026 | 10.47 | 13.39 | 10.28 | 12.56 | 28.70M |
| Oct 2, 2026 | 10.80 | 10.86 | 10.33 | 10.46 | 4.02M |
| Oct 1, 2026 | 10.75 | 10.98 | 10.55 | 10.60 | 3.15M |
| Sep 30, 2026 | 10.85 | 11.10 | 10.54 | 10.81 | 4.56M |
| Sep 29, 2026 | 10.80 | 11.11 | 10.41 | 10.82 | 4.07M |
| Sep 28, 2026 | 10.50 | 10.98 | 10.26 | 10.80 | 4.46M |
| Sep 25, 2026 | 10.62 | 10.79 | 10.34 | 10.63 | 3.91M |
| Sep 24, 2026 | 10.43 | 10.85 | 10.38 | 10.60 | 4.35M |
| Sep 23, 2026 | 10.79 | 10.95 | 10.47 | 10.55 | 5.77M |
| Sep 22, 2026 | 10.39 | 11.09 | 10.15 | 10.83 | 7.58M |
| Sep 21, 2026 | 10.38 | 10.70 | 10.21 | 10.41 | 6.13M |
About Novavax
Novavax (NVAX) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in GAITHERSBURG, MD. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1000694.
NVAX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gregg H Alton | Director | Jun 23, 2026 |
| Richard Douglas | Director | Jun 23, 2026 |
| John C Jacobs | President and CEO | Mar 9, 2026 |
| Rachel K. King | Director | Jun 23, 2026 |
| Margaret G Mcglynn | Director | Jun 23, 2026 |
| David M Mott | Director | Jun 23, 2026 |
| Charles W. Newton | Director | Jun 23, 2026 |
| Richard J Rodgers | Director | Jun 23, 2026 |
| John W. Shiver | Director | Jun 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Mark J Casey | EVP, Chief Legal Officer | Mar 9, 2026 |
| Ruxandra Draghia-Akli | EVP, Research & Development | Mar 9, 2026 |
| John C Jacobs | President and CEO | Mar 9, 2026 |
| James Patrick Kelly | EVP, CFO and Treasurer | Mar 9, 2026 |
| Elaine O'Hara | EVP, Chief Strategy Officer | Mar 9, 2026 |
| Robert Edward Walker | EVP, R&D | Apr 16, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
NVAX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.12B | $440.30M | 2.58 | $-244.63M |
| Dec 31, 2024 | $682.16M | $-187.50M | -1.23 | $-87.26M |
| Dec 31, 2023 | $983.71M | $-545.06M | -5.41 | $-713.97M |
| Dec 31, 2022 | $1.98B | $-657.94M | -8.42 | $-415.94M |
| Dec 31, 2021 | — | $-1.74B | -23.44 | $322.95M |
Latest balance sheet: total assets $955.58M, total liabilities $1.15B, cash $191.46M (as of Jun 30, 2026).
NVAX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $7.74 |
| May 6, 2026 | 8-K Item 2.02 (results) | $9.36 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $11.19 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $7.75 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $7.59 |
| Aug 6, 2025 | 8-K Item 2.02 (results) | $7.58 |
| May 8, 2025 | 8-K Item 2.02 (results) | $6.66 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $7.06 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $8.61 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $8.46 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 10, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on NVAX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.